RSABE/ABEL in a TSD: Science fiction [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2014-05-24 00:39 (4046 d 15:09 ago) – Posting: # 13002
Views: 11,282

Hi Yung-jin,

❝ […] It sounds like that it is possible to implement all these using R or into bear together with PowerTOST.


Yes, why not? ;-)

❝ OK, the example is from WLN.


The example is from Potvin’s paper.

❝ CVintra = 18.21% (for Cmax?) with 12 subjects.


They didn’t state which PK metric the data covers.

❝ So it is not a HVD, isn't it?


The CV of the pooled data set (n=20) is 21.67%. So HVD is unlikely.

❝ Does EMA or FDA accept the two-stage BE if it is the case?


Hopefully only in such cases (conventional unscaled ABE). I have heard that some people already naïvely unreflecting submitted protocols in the EU with replicate designs for ABEL, believing that αadj 0.0294 would maintain the overall risk type I ≤0.05. Crap.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
46 visitors (0 registered, 46 guests [including 8 identified bots]).
Forum time: 15:49 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5